Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer

Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year. Overtreatment of indolent disease also results in significant morbidity. Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21) and PTEN (10q23), gains of AR (the androgen receptor gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters. Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.

Citing Articles

Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.

Morgan R, Hazard E, Savage S, Halbert C, Gattoni-Celli S, Hardiman G Genes (Basel). 2025; 16(2).

PMID: 40004558 PMC: 11855151. DOI: 10.3390/genes16020229.

p27 and Tumors: Characterization of Variants Identified in MEN4 and Breast Cancer.

Bencivenga D, Stampone E, Azhar J, Parente D, Ali W, Del Vecchio V Cells. 2025; 14(3).

PMID: 39936980 PMC: 11817124. DOI: 10.3390/cells14030188.

Decoding the functional impact of the cancer genome through protein-protein interactions.

Fu H, Mo X, Ivanov A Nat Rev Cancer. 2025; 25(3):189-208.

PMID: 39810024 DOI: 10.1038/s41568-024-00784-6.

E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic β cells.

Oguh A, Haemmerle M, Sen S, Rozo A, Shrestha S, Cartailler J Genes Dev. 2025; 39(3-4):261-279.

PMID: 39797759 PMC: 11789638. DOI: 10.1101/gad.352010.124.

The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Pedrani M, Barizzi J, Salfi G, Nepote A, Testi I, Merler S Int J Mol Sci. 2025; 26(1.

PMID: 39796175 PMC: 11719667. DOI: 10.3390/ijms26010318.

References

Daskivich T, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A . Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117(10):2058-66. DOI: 10.1002/cncr.25751. View

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

Stransky N, Egloff A, Tward A, Kostic A, Cibulskis K, Sivachenko A . The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-60. PMC: 3415217. DOI: 10.1126/science.1208130. View

Kibel A, Suarez B, Belani J, Oh J, Webster R, Brophy-Ebbers M . CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003; 63(9):2033-6. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Donjacour A, Sciavolino P, Kim M, Desai N, Young P, Norton C . Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999; 13(8):966-77. PMC: 316645. DOI: 10.1101/gad.13.8.966. View

Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A . The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-20. PMC: 3075885. DOI: 10.1038/nature09744. View

Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

Wang C, Pan Y, Wang B . Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. Development. 2010; 137(12):2001-9. PMC: 2875842. DOI: 10.1242/dev.052126. View

10.

Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner J . Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011; 71(21):6738-6748. PMC: 4081454. DOI: 10.1158/0008-5472.CAN-11-1882. View

11.

Griffith O, Montgomery S, Bernier B, Chu B, Kasaian K, Aerts S . ORegAnno: an open-access community-driven resource for regulatory annotation. Nucleic Acids Res. 2007; 36(Database issue):D107-13. PMC: 2239002. DOI: 10.1093/nar/gkm967. View

12.

Kozomara A, Griffiths-Jones S . miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2010; 39(Database issue):D152-7. PMC: 3013655. DOI: 10.1093/nar/gkq1027. View

13.

Espina V, Wulfkuhle J, Calvert V, VanMeter A, Zhou W, Coukos G . Laser-capture microdissection. Nat Protoc. 2007; 1(2):586-603. DOI: 10.1038/nprot.2006.85. View

14.

Yang J, Hung M . A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res. 2009; 15(3):752-7. PMC: 2676228. DOI: 10.1158/1078-0432.CCR-08-0124. View

15.

Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q . BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010; 18(6):568-79. PMC: 3030476. DOI: 10.1016/j.ccr.2010.10.030. View

16.

Zhou R, Bonneaud N, Yuan C, de Santa Barbara P, Boizet B, Schomber T . SOX9 interacts with a component of the human thyroid hormone receptor-associated protein complex. Nucleic Acids Res. 2002; 30(14):3245-52. PMC: 135763. DOI: 10.1093/nar/gkf443. View

17.

He W, Sciavolino P, Wing J, Augustus M, Hudson P, Meissner P . A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997; 43(1):69-77. DOI: 10.1006/geno.1997.4715. View

18.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P . Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2010; 21(1):56-67. PMC: 3012926. DOI: 10.1101/gr.110684.110. View

19.

Mosquera J, Mehra R, Regan M, Perner S, Genega E, Bueti G . Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-11. PMC: 3717524. DOI: 10.1158/1078-0432.CCR-08-2927. View

20.

Fujita P, Rhead B, Zweig A, Hinrichs A, Karolchik D, Cline M . The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2010; 39(Database issue):D876-82. PMC: 3242726. DOI: 10.1093/nar/gkq963. View